NCT00378482View on ClinicalTrials.gov

A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

March 5, 2007

Primary Completion Date

October 27, 2023

Study Completion Date

October 27, 2023

Conditions
Colorectal NeoplasmsMelanomaProstatic NeoplasmsRenal Cell CarcinomaNeoplasmsPatients Who Have/Have Had Melanoma and Other Tumors
Interventions
DRUG

CP-675,206 (Tremelimumab)

15 mg/kg IV every 3 months as long as required

Trial Locations (6)

10016

Research Site, New York

33612

Research Site, Tampa

48109

Research Site, Ann Arbor

77030

Research Site, Houston

90024

Research Site, Los Angeles

NE7 7DN

Research Site, Newecastle Upon Tyne

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY